Typical antipsychotics work by blocking dopamine receptors in the brain, specifically the D2 subtype. Their therapeutic effect kicks in when they occupy roughly 60 to 65% of D2 receptors in a key brain region called the dorsal striatum. This same mechanism, applied too aggressively, is also what causes most of their side effects.
The Core Mechanism: Dopamine Blockade
Dopamine is a chemical messenger involved in reward, motivation, movement, and hormonal regulation. In conditions like schizophrenia, excess dopamine signaling in certain brain areas is thought to drive positive symptoms: hallucinations, delusions, and disorganized thinking. Typical antipsychotics work by physically sitting on D2 receptors, preventing dopamine from binding and passing along its signal.
The problem is that dopamine doesn’t operate in just one part of the brain. It runs through several distinct pathways, and these drugs can’t selectively target only the pathway responsible for psychosis. When they block D2 receptors everywhere, the therapeutic benefits come bundled with a predictable set of side effects.
Four Dopamine Pathways, Four Sets of Effects
The brain has three major dopamine systems relevant to antipsychotic treatment, plus a fourth that’s often discussed alongside them. Each pathway handles different functions, and blocking dopamine in each one produces different results.
The mesolimbic pathway is the target. Overactive dopamine signaling here is associated with hallucinations and delusions. Blocking D2 receptors in this pathway is what reduces these positive symptoms, and it’s the entire reason these drugs exist.
The nigrostriatal pathway controls voluntary movement. When D2 receptors are blocked here, the result is drug-induced movement disorders collectively called extrapyramidal symptoms. These include muscle stiffness resembling Parkinson’s disease, involuntary muscle contractions, and a distressing sense of inner restlessness called akathisia. This pathway is also where tardive dyskinesia originates with long-term use.
The tuberoinfundibular pathway runs between the brain’s hypothalamus and the pituitary gland, where dopamine normally keeps the hormone prolactin in check. Block dopamine here, and prolactin levels rise. In women, this can cause breast milk production outside of pregnancy, missed or irregular periods, vaginal dryness, and fertility problems. Prevalence rates of 50% or higher have been reported for some of these symptoms in women taking typical antipsychotics. Men can also experience breast changes, though less commonly.
The mesocortical pathway serves the prefrontal cortex and is involved in motivation, planning, and emotional expression. Typical antipsychotics do very little to help here. Negative symptoms of schizophrenia (flat affect, social withdrawal, lack of motivation) and cognitive difficulties are only minimally responsive to these drugs, which is one of the major limitations of first-generation treatment.
The Narrow Therapeutic Window
What makes typical antipsychotics tricky to use is how close the therapeutic dose sits to the dose that causes movement problems. Antipsychotic effects begin at around 60 to 65% D2 receptor occupancy, but extrapyramidal symptoms start appearing at around 80% occupancy. That leaves a fairly narrow band where the drug is working without causing significant neurological side effects. A majority of patients given standard therapeutic doses of typical antipsychotics develop at least some acute extrapyramidal symptoms.
High-Potency vs. Low-Potency Drugs
Not all typical antipsychotics feel the same to patients, because they don’t all bind to the same mix of receptors. They’re generally divided into high-potency and low-potency categories, using chlorpromazine as the reference point.
High-potency drugs like haloperidol and fluphenazine bind D2 receptors very tightly at low doses. Just 2mg of haloperidol produces the same antipsychotic effect as 100mg of chlorpromazine. Because they’re so focused on D2 receptors, these drugs are more likely to cause movement disorders but less likely to cause sedation or drops in blood pressure.
Low-potency drugs like chlorpromazine and thioridazine require much higher doses to achieve the same D2 blockade. They also bind heavily to histamine receptors (causing sedation and weight gain), muscarinic receptors (causing dry mouth, constipation, and blurred vision), and alpha-1 adrenergic receptors (causing dizziness and low blood pressure when standing). They produce fewer movement side effects but more of everything else.
Movement Disorders: Timing and Risk
Extrapyramidal symptoms fall into two categories based on when they appear. Acute symptoms show up within days or weeks of starting the medication or increasing the dose. These include drug-induced parkinsonism (stiffness, tremor, slowed movement), acute dystonia (sudden, sustained muscle contractions, often in the neck or jaw), and akathisia (an unbearable urge to move). In large analyses, about 20% of patients on antipsychotics develop parkinsonism and 11% develop akathisia.
Tardive dyskinesia is the long-term concern. It involves involuntary, repetitive movements, most often of the face, tongue, and jaw, and it develops after months or years of treatment. About 7% of patients across all antipsychotic types develop it, but the risk with typical antipsychotics specifically is much higher. In older adults taking first-generation drugs, studies have found the incidence reaches 23% after one year, 42% after two years, and 57% after three years. Tardive dyskinesia can persist even after the drug is stopped, which makes it one of the most serious risks of long-term treatment.
Neuroleptic Malignant Syndrome
The most dangerous reaction to typical antipsychotics is neuroleptic malignant syndrome, a rare but life-threatening emergency. It involves four hallmark features: altered mental status (confusion or reduced consciousness), high fever, severe muscle rigidity, and unstable vital signs including rapid heart rate and fluctuating blood pressure. Early reports put the mortality rate above 30%, but with better recognition and supportive care, it has dropped below 10%.
How They Differ From Atypical Antipsychotics
Atypical (second-generation) antipsychotics also block D2 receptors, but they add strong blockade of serotonin 5-HT2A receptors. This serotonin-to-dopamine affinity ratio appears to be what makes them “atypical.” Serotonin 5-HT2A receptors modulate dopamine release differently across brain regions, so blocking them seems to loosen dopamine suppression in the movement and hormonal pathways while maintaining it in the areas that drive psychosis. The practical result is a lower rate of extrapyramidal symptoms and less prolactin elevation, though atypical drugs carry their own risks, particularly metabolic side effects like weight gain and blood sugar changes.
Typical antipsychotics lack this serotonin counterbalance. They suppress dopamine signaling broadly and indiscriminately, which is why their side effect profile tilts so heavily toward movement and hormonal problems.
What Typical Antipsychotics Are Used For
Schizophrenia remains the primary indication, particularly for managing acute psychotic episodes and preventing relapse. But several of these drugs carry approvals for other conditions. Haloperidol is approved for Tourette syndrome and severe behavioral problems in children. Chlorpromazine is approved for the manic phase of bipolar disorder, hyperactivity, and severe behavioral disturbances in children as young as one year old. Pimozide is specifically approved for Tourette syndrome. Trifluoperazine and prochlorperazine carry approvals for generalized nonpsychotic anxiety in adults, though they’re rarely first-line choices for that purpose today.
Despite the arrival of newer drugs, typical antipsychotics remain in wide use globally. They’re effective at controlling positive psychotic symptoms, available in long-acting injectable forms for patients who have difficulty with daily pills, and significantly less expensive than most atypical alternatives.